Lake Street analyst Thomas Flaten raised the firm’s price target on Harrow (HROW) to $70 from $42 and keeps a Buy rating on the shares. The company’s investor day on Friday reinforced the firm’s confidence in the company’s ability to scale its business to $250M-plus in quarterly revenue by Q4 of 2027, the analyst tells investors. “It is hard to bet against success and Harrow has had plenty of it,” adds the firm, which would remain buyers of the Harrow shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health Secures New $40 Million Credit Facility
- Harrow Health’s Promising Growth Trajectory: Buy Rating Supported by Strategic Initiatives and Product Expansion
- Harrow Health’s Promising Growth Trajectory: Analyst Recommends ‘Buy’ Amid Strategic Revenue Projections and Product Enthusiasm
- Harrow Health Hosts Investor Day Presentation
- Harrow targets $250M+ in quarterly revenue by 4Q27